The DCCT randomised trial compared insulin therapy with strict glycaemic control versus less strict insulin therapy in patients with type 1 diabetes. The trial itself lasted more than 6 years, and most of the patients were subsequently followed up for another 4 years. The initial benefit of strict glycaemic control on the onset or worsening of diabetic retinopathy and nephropathy does appear to persist in the long term